US Patent

US10052267 — Topical glycopyrrolate formulations

Method of Use · Assigned to Rose U LLC · Expires 2028-10-17 · 2y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects individually packaged topical formulations containing 0.25-6% glycopyrrolate for treating hyperhidrosis.

USPTO Abstract

Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2398 — glycopyrronium-tosylate

Patent Metadata

Patent number
US10052267
Jurisdiction
US
Classification
Method of Use
Expires
2028-10-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Rose U LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.